CEPI (Coalition for Epidemic Preparedness Innovations)
Matthew Saunders is a highly experienced toxicologist with a career spanning several leading organizations in the field. Currently serving as a Toxicologist at the Coalition for Epidemic Preparedness Innovations (CEPI) since 2024 and as Associate Director of Toxicology at GSK since January 2023, Matthew has managed global teams and contributed to the design and review of preclinical toxicology studies. Prior roles include Senior Toxicologist at Labcorp, where guidance was provided on various non-clinical mammalian studies, and Team Leader at Envigo, overseeing a team of toxicology professionals. Matthew's foundational experience as Senior Study Manager at Huntingdon Life Sciences and earlier positions, including a Trainee Manager role and Laboratory Technician, complimented by a Master's degree in Applied Toxicology from the University of Surrey and a Bachelor's degree in Environmental Biology from Anglia Ruskin University, underline a strong expertise in toxicology and regulatory compliance.
This person is not in any teams
This person is not in any offices
CEPI (Coalition for Epidemic Preparedness Innovations)
2 followers
CEPI is an innovative partnership between public, private, philanthropic, and civil organisations, launched at Davos in 2017, to develop vaccines against future epidemics. Prior to COVID-19, CEPI’s work focused on developing vaccines against the Ebola Virus Disease, Lassa virus, Middle East Respiratory Syndrome coronavirus, Nipah virus, Rift Valley Fever virus and Chikungunya virus. It has over 20 vaccine candidates against these pathogens in development. CEPI has also invested in new platform technologies for rapid vaccine development against unknown pathogens (Disease X). During the COVID-19 pandemic, CEPI initiated multiple programmes to develop vaccines against SARS-CoV-2 and its variants with a focus on speed, scale, and access. These programmes leverage the rapid response platforms developed by CEPI’s partners prior to the emergence of COVID-19, as well as new collaborations. The aim is to advance clinical development of a diverse portfolio of safe and effective COVID-19 candidates and to enable fair allocation of these vaccines worldwide through COVAX. CEPI’s 5-year plan lays out a $3.5 billion roadmap to compress vaccine development timelines to 100 days, develop a broadly protective vaccine against COVID-19 and other Betacoronaviruses, and create a “library” of vaccine candidates for use against known and unknown pathogens. The plan is available at www.endpandemics.cepi.net